How do I get compassionate use access for HER2-Low Breast Cancer drugs not yet approved

Accessing Compassionate Use for HER2-Low Breast Cancer Treatments

I appreciate this important question. Let me walk you through how compassionate use works for HER2-low breast cancer and what steps you can take.

Understanding Your Situation

HER2-low breast cancer is an emerging treatment area. Trastuzumab deruxtecan (Enhertu), an antibody-drug conjugate (a drug that combines an antibody with a toxin), has recently been FDA-approved for HER2-low breast cancer based on clinical trial data showing improved overall survival compared to chemotherapy alone. However, if you're looking at other investigational HER2-directed therapies not yet approved, compassionate use may be an option.

How Compassionate Use Works

According to resources on cancer treatment access, compassionate use (also called "expanded access") is a regulatory pathway that allows patients with serious or life-threatening conditions to access investigational drugs outside of clinical trials when:

1. You've exhausted standard treatment options - You've typically tried approved therapies first
2. You're healthy enough for treatment - You must be able to move around and function at least part of the day
3. No comparable alternative exists - There's no other satisfactory treatment available
4. There's a reasonable basis - Some evidence suggests the drug might help

The Process: Step-by-Step

Step 1: Work with Your Oncologist Your doctor must initiate the compassionate use request. This is critical—you cannot access these drugs directly. Your oncologist needs to:

• Review your specific tumor characteristics (HER2 expression level, other biomarkers)
• Determine if an investigational drug aligns with your tumor's profile
• Prepare documentation of your medical history and why standard options haven't worked

Step 2: Request from the Drug Manufacturer Your doctor's team (usually a billing professional or patient advocate) contacts the pharmaceutical company making the drug. According to treatment access experts, companies are often "generally helpful" and may even assist with paperwork.

Step 3: FDA Approval The FDA must approve the compassionate use request. This can take weeks to months, though some organizations report approvals in as little as 2 hours through expedited pathways like the FDA's Project Facilitate.

Step 4: Insurance & Cost Considerations This is a major barrier. Many insurance companies won't cover off-label drugs. However:

• Some manufacturers have patient assistance programs that provide drugs free or at reduced cost
• Your doctor's office may negotiate with insurance
• Some specialized cancer centers have relationships with manufacturers for cost coverage

Specific Resources for HER2-Low Breast Cancer

According to Cancer Patient Lab webinars on personalized cancer treatment:

Patient Assistance Organizations that can help navigate this process:

• Anova - Specializes in helping patients access compassionate use and clinical trials
• Cancer Commons - Provides patient navigation and treatment matching
• xCures - Helps identify personalized treatment options

These groups can:

• Help your doctor make the case to insurance companies
• Connect you with "pioneering prescribers" (oncologists experienced with off-label HER2 therapies)
• Assist with FDA paperwork and manufacturer negotiations

Questions to Ask Your Oncologist

To move this forward, bring these specific questions to your care team:

1. "Based on my HER2 expression level and other biomarkers, are there investigational HER2-directed drugs that might be appropriate for me?"

2. "Would you be willing to pursue compassionate use access if a drug seems promising for my specific tumor profile?"

3. "What patient assistance or advocacy organizations do you work with to help navigate compassionate use requests?"

4. "If we identify a candidate drug, what's your timeline for submitting a compassionate use request, and what documentation do you need from me?"

5. "How do we handle insurance coverage? Should we contact the manufacturer's patient assistance program first?"

Important Considerations

⚠️ Timing matters: Compassionate use requests can take weeks or months. If your disease is progressing rapidly, discuss whether clinical trials might be faster alternatives.

⚠️ Evidence requirement: The FDA wants to see that there's a reasonable scientific basis for the drug choice. Having your tumor tested for specific biomarkers (HER2 protein levels, other mutations) strengthens your case.

⚠️ Not guaranteed: Even with a strong case, the FDA can deny compassionate use requests if they believe there isn't sufficient evidence the drug will help.

Alternative Pathways to Consider

If compassionate use is delayed or denied:

• Clinical trials - May offer faster access to investigational HER2 drugs
• Patient assistance programs - Some manufacturers provide approved drugs free through these programs
• Off-label prescribing - Your doctor can prescribe FDA-approved drugs for unapproved uses (though insurance may not cover it)

Key Takeaway

Compassionate use is possible for HER2-low breast cancer, but it requires your oncologist's active participation and often involves navigating insurance barriers. Starting the conversation with your care team and connecting with patient advocacy organizations like Anova or Cancer Commons can significantly improve your chances of access.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.